Exploration of the Clinical Relevance of Gut Microbiota to Myocardial Infarction Based on the Microbiota-gut-heart Axis
10.3870/j.issn.1004-0781.2025.12.021
- VernacularTitle:基于微生物-肠-心轴探讨肠道菌群与心肌梗死的临床相关性
- Author:
Yan CHEN
1
;
Xia WANG
;
Hang XU
;
Lin ZHOU
Author Information
1. 南京大学医学院附属鼓楼医院药学部,南京 210008
- Publication Type:Journal Article
- Keywords:
Microbiota-gut-heart axis;
Gut Microbiota;
Myocardial infarction;
Trimethylamine N-oxide;
Phenylacetylglutamine
- From:
Herald of Medicine
2025;44(12):2022-2029
- CountryChina
- Language:Chinese
-
Abstract:
Myocardial infarction(MI)is one of the most common cardiovascular diseases(CVD)in clinic.Its morbidity,disability rate and mortality are remain high,making it an urgent challenge to address.In recent years,a growing number of studies have found that gut microbiota and their metabolites are closely related to the occurrence and development of MI.Some gut metabolites such as trimethylamine N-oxide(TMAO)and phenylacetylglutamine(PAGln)can predict major adverse cardiovascular events(MACE),including MI.In this review,the effects of gut microbiota on MI were investigated based on microbial-gut-heart-axis(MGHA).The results showed that plasma concentrations of gut metabolites(short-chain fatty acids,TMAO,PAGln、bile acids)had significant clinical correlation with MI,and had different effects on the occurrence of MI.Additionally,drug therapy,fecal microbial transplantation,changes in living and eating habits can all affect the composition of gut microbiota and the concentration of metabolites,thus providing new insights for the treatment of MI.
